DR. MATTHEW D MCLEOD, MD
Radiology at Parkman St, Boston, MA
License number
Massachusetts 270153
Category
Radiology
Type
Plastic and Reconstructive Surgery
Address
Address
15 Parkman St #4-435, Boston, MA 02114
Phone
(617) 726-7712
Personal information
See more information about MATTHEW D MCLEOD at radaris.comName
Address
Phone
46 Walker St, Charlestown, MA 02129
12 Winter St, Reading, MA 01867
111 East St, Methuen, MA 01844
3 Prentiss St, Cambridge, MA 02140
371 Shawmut Ave, Boston, MA 02118
Professional information
Treating Melanoma With Bis(Thiohydrazide Amides)
US Patent:
2008017, Jul 24, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894261
Inventors:
Martin Williams - Cambridge MA, US
Matthew McLeod - Boston MA, US
Keizo Koya - Chestnut Hill MA, US
Matthew McLeod - Boston MA, US
Keizo Koya - Chestnut Hill MA, US
International Classification:
A61K 31/397, A61K 31/165, A61P 35/00
US Classification:
51421006, 514599
Abstract:
Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
Treating Melanoma With Bis(Thiohydrazide Amides)
US Patent:
2008022, Sep 18, 2008
Filed:
Aug 20, 2007
Appl. No.:
11/894270
Inventors:
Matthew McLeod - Boston MA, US
International Classification:
A61K 31/165, A61K 31/337, A61K 33/24, A61K 31/655, A61K 38/21, A61K 38/20, A61K 31/4188, A61K 31/662, A61K 31/4412, A61P 35/00
US Classification:
424 852, 514599, 514449, 424649, 514151, 424 854, 514393, 514119, 514350
Abstract:
Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.
Combination Cancer Therapy With Bis(Thiohydrazide) Amide Compounds
US Patent:
8017654, Sep 13, 2011
Filed:
Apr 13, 2006
Appl. No.:
11/918357
Inventors:
Thomas A. Dahl - Cambridge MA, US
Matthew McLeod - Boston MA, US
Matthew McLeod - Boston MA, US
Assignee:
Synta Pharmaceuticals Corp. - Lexington MA
International Classification:
A01N 37/18, A61K 31/16, C07D 305/00, C07D 407/00, C07D 493/00, C07C 241/00, C07C 243/00, C07C 249/00, C07C 251/00
US Classification:
514615, 549510, 564149
Abstract:
A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/m2 to 315 μmol/m2 (e. g. , equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 μmol/m2 and about 1722 μmol/m2 (e. g. , Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R-Rare independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, and/or Rand Rtaken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R-Rare independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.
Combination Cancer Therapy With Bis(Thiohydrazide) Amide Compounds
US Patent:
2012023, Sep 13, 2012
Filed:
Sep 12, 2011
Appl. No.:
13/230315
Inventors:
Thomas A. Dahl - Cambridge MA, US
Matthew McLeod - Boston MA, US
Matthew McLeod - Boston MA, US
Assignee:
Synta Pharmaceuticals Corp. - Lexington MA
International Classification:
A61K 31/337, A61P 35/00
US Classification:
514449
Abstract:
Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 μmol/mto 315 μmol/m; and a bis(thiohydrazide amide) compound in an amount between about 1473 μmol/mand about 1722 μmol/m.